Press Releases

All Releases
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
Aug 21, 2014
PDF 12.3 KB
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Jul 31, 2014
PDF 27.0 KB
Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
Jul 22, 2014
PDF 7.7 KB
Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients
Jun 19, 2014
PDF 15.6 KB
US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK
Jun 12, 2014
PDF 13.7 KB
Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists
Jun 11, 2014
PDF 11.1 KB
Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting
Jun 1, 2014
PDF 13.1 KB
Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting
May 31, 2014
PDF 15.9 KB
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
May 19, 2014
PDF 12.5 KB
Nektar Therapeutics To Present at the UBS 2014 Global Healthcare Conference in New York City
May 16, 2014
PDF 7.2 KB
Nektar Therapeutics Reports Financial Results for the First Quarter of 2014
May 7, 2014
PDF 26.2 KB
Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday, May 7, 2014, After Close of U.S.-Based Financial Markets
May 1, 2014
PDF 7.8 KB
Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR
Apr 9, 2014
PDF 15.1 KB
Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
Feb 26, 2014
PDF 26.1 KB
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets
Feb 19, 2014
PDF 7.9 KB
Nektar Therapeutics Prices Public Offering of Common Stock
Jan 22, 2014
PDF 5.9 KB
Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock
Jan 21, 2014
PDF 6.4 KB
Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Fluorouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium
Jan 18, 2014
PDF 13.7 KB
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Jan 14, 2014
PDF 15.5 KB
First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain
Jan 14, 2014
PDF 14.9 KB
Showing 1-20 of 196 Page: 1 2 3 ... 10  Next 20
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide